Latest earnings report was released after the close ThursdayCompany Profile and PipelineAnalyst actions and commentsOur thoughts on the stock and a chart CymaBay Therapeutics $CBAY reported earnings after the close on Thursday. On Friday, the stock rose over 10% on the news. Q4 EPS of ($0.11) , beating estimates by $0.08Q4 Revenue came in at $5.2 million vs a consensus estimate of $1.25 millionCash, cash equivalents and marketable securities came in at $97.2 million on December 31, 2017, compared to just $17.0 million a year ago. This is expected to fund the company into 2021. "About CymaBay We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC) and the epidemic in NonAlcoholic SteatoHepatitis (NASH). A Phase 2 study of seladelpar demonstrated clinical activity and established proof-of-concept in PBC. We are now conducting a second Phase 2 study to support dose selection for Phase 3 development. Seladelpar has received an orphan designation from the U.S. Food and Drug Administration and the PRIority MEdicine (PRIME) status from the European Medicines Agency. Clinical development for NASH is currently being planned. Arhalofenate is a potential urate-lowering anti-flare therapy for gout that is Phase 3 ready. In December 2016, Kowa Pharmaceuticals America, Inc. licensed U.S. rights for arhalofenate and is responsible for all development and commercialization costs in the U.S. CymaBay retains full development and commercialization rights for outside the U.S. and intends to partner in those geographies. Our pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases." (Source CymaBay company site) Piper Jaffray reiterated its Buy rating on Friday with a $16.00 price target. SunTrust reiterated its Buy rating on Friday with a $19.00 price target. "Would be a strong buyer" Cantor Fitzgerald reiterated their buy rating on Friday morning with a $16.00 price target. This stock has done very well and should continue to do so. It is making good progress with its drug pipeline. Analysts continue to support buying the stock. According to the earnings report, the company has enough cash to fund operations into 2021. This should reduce concerns about stock offerings and dilutions common to Biotech stocks. Could not find a negative except for a valuation concern. Looking at the chart, it made large gains December thru March. $CBAY, CymaBay Therapeutics Inc. / H3 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button.Feel free to leave any comments or opinions.Follow us and check back occasionally for additional articles or posts.